BR9911073A - Uso de uma composição compreendendo formoterol e budesonida para a prevenção ou tratamento de uma condição aguda de asma - Google Patents

Uso de uma composição compreendendo formoterol e budesonida para a prevenção ou tratamento de uma condição aguda de asma

Info

Publication number
BR9911073A
BR9911073A BR9911073-3A BR9911073A BR9911073A BR 9911073 A BR9911073 A BR 9911073A BR 9911073 A BR9911073 A BR 9911073A BR 9911073 A BR9911073 A BR 9911073A
Authority
BR
Brazil
Prior art keywords
composition
budesonide
prevention
treatment
asthma condition
Prior art date
Application number
BR9911073-3A
Other languages
English (en)
Inventor
Tommy Ekstrom
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20411658&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR9911073(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of BR9911073A publication Critical patent/BR9911073A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds

Abstract

<B>"USO DE UMA COMPOSIçãO COMPREENDENDO FORMOTEROL E BUDESONIDA PARA A PREVENçãO OU TRATAMENTO DE UMA CONDIçãO AGUDA DE ASMA"<D>. A presente invenção se refere ao uso de uma composição para alívio sintomático, quando necessário, compreendendo uma mistura de (a) um primeiro ingrediente ativo, que é o formoterol, um sal farmaceuticamente aceitável ou um solvato do mesmo ou um solvato de tal sal; e b) um segundo ingrediente ativo que é a budesonida, para a fabricação de um medicamento para uso na prevenção ou tratamento de uma condição aguda de asma e/ou uma condição intermitente de asma e/ou episódios de asma crónica. A inveção se refere ainda a um método para prevenção ou tratamento de uma condição aguda de asma e/ou uma condição intermitente de asma e/ou episódios de asma crónica, mediante administração por inalação, de uma composição compreendendo os primeiro e segundo ingredientes ativos, conforme definido anteriormente.
BR9911073-3A 1998-06-11 1999-06-10 Uso de uma composição compreendendo formoterol e budesonida para a prevenção ou tratamento de uma condição aguda de asma BR9911073A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9802073A SE9802073D0 (sv) 1998-06-11 1998-06-11 New use
PCT/SE1999/001031 WO1999064014A1 (en) 1998-06-11 1999-06-10 Use of a composition comprising formoterol and budesonide for the prevention or treatment of an acute condition of asthma

Publications (1)

Publication Number Publication Date
BR9911073A true BR9911073A (pt) 2001-02-20

Family

ID=20411658

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9911073-3A BR9911073A (pt) 1998-06-11 1999-06-10 Uso de uma composição compreendendo formoterol e budesonida para a prevenção ou tratamento de uma condição aguda de asma

Country Status (35)

Country Link
US (2) US20010049396A1 (pt)
EP (3) EP1085877B1 (pt)
JP (1) JP2002517450A (pt)
KR (1) KR20010052721A (pt)
CN (1) CN100389771C (pt)
AR (1) AR018410A1 (pt)
AT (1) ATE389409T1 (pt)
AU (1) AU771715B2 (pt)
BR (1) BR9911073A (pt)
CA (1) CA2334411C (pt)
CY (1) CY1110376T1 (pt)
CZ (1) CZ300874B6 (pt)
DE (1) DE69938390T2 (pt)
DK (1) DK1085877T3 (pt)
EE (1) EE05661B1 (pt)
ES (1) ES2302384T3 (pt)
HK (1) HK1035145A1 (pt)
HU (1) HUP0103108A3 (pt)
ID (1) ID27937A (pt)
IL (2) IL139921A0 (pt)
IS (1) IS5752A (pt)
MY (1) MY129281A (pt)
NO (3) NO20006253L (pt)
NZ (1) NZ536279A (pt)
PL (1) PL344665A1 (pt)
PT (1) PT1085877E (pt)
RU (1) RU2222332C2 (pt)
SA (1) SA99200234B1 (pt)
SE (1) SE9802073D0 (pt)
SK (1) SK286252B6 (pt)
TR (1) TR200003666T2 (pt)
TW (1) TWI252756B (pt)
UA (1) UA87956C2 (pt)
WO (1) WO1999064014A1 (pt)
ZA (1) ZA200006943B (pt)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9703407D0 (sv) 1997-09-19 1997-09-19 Astra Ab New use
SE9802073D0 (sv) 1998-06-11 1998-06-11 Astra Ab New use
DZ2947A1 (fr) 1998-11-25 2004-03-15 Chiesi Farma Spa Inhalateur à compteur de dose sous pression.
US6004537A (en) * 1998-12-18 1999-12-21 Baker Norton Pharmaceuticals, Inc. Pharmaceutical solution aerosol formulations containing fluoroalkanes, budesonide and formoterol
IT1313553B1 (it) 1999-07-23 2002-09-09 Chiesi Farma Spa Formulazioni ottimizzate costituite da soluzioni di steroidi dasomministrare per inalazione.
IT1317846B1 (it) 2000-02-22 2003-07-15 Chiesi Farma Spa Formulazioni contenenti un farmaco anticolinergico per il trattamentodella broncopneumopatia cronica ostruttiva.
GB0009584D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Pharmaceutical compositions
IT1318514B1 (it) * 2000-05-12 2003-08-27 Chiesi Farma Spa Formulazioni contenenti un farmaco glucocorticosteroide per iltrattamento di patologie broncopolmonari.
GB0012261D0 (en) * 2000-05-19 2000-07-12 Astrazeneca Ab Novel process
GB0012260D0 (en) 2000-05-19 2000-07-12 Astrazeneca Ab Novel composition
ME00220B (me) 2000-05-22 2010-10-10 Chiesi Farm Spa Stabilne farmaceutske formulacije rastvora za inhalatore odmjerene doze pod pritiskom
TR200401980T4 (tr) 2001-07-02 2004-09-21 Chiesi Farmaceutici S.P.A. Aerosol olarak uygulama için en uygun hale getirilmiş tobramisin formülasyonu
GB0208742D0 (en) 2002-04-17 2002-05-29 Bradford Particle Design Ltd Particulate materials
EP1446104B2 (en) * 2001-11-01 2011-08-03 Novartis AG Spray drying methods
FI20020126A0 (fi) * 2002-01-23 2002-01-23 Orion Corp Koostumuksia pulmonaaliseen antoon
SE0200312D0 (sv) * 2002-02-01 2002-02-01 Astrazeneca Ab Novel composition
US9339459B2 (en) 2003-04-24 2016-05-17 Nektar Therapeutics Particulate materials
GB0219512D0 (en) * 2002-08-21 2002-10-02 Norton Healthcare Ltd Inhalation compositions with high drug ratios
GB0219511D0 (en) 2002-08-21 2002-10-02 Norton Healthcare Ltd Method of preparing dry powder inhalation compositions
JP4744876B2 (ja) * 2002-08-21 2011-08-10 ノートン・ヘルスケアー リミテッド 乾燥粉末吸入組成物の製造方法
TWI359675B (en) 2003-07-10 2012-03-11 Dey L P Bronchodilating β-agonist compositions
EP1595531A1 (en) 2004-05-13 2005-11-16 CHIESI FARMACEUTICI S.p.A. Stable pharmaceutical solution formulations for pressurized metered dose inhalers
US20050207983A1 (en) 2004-03-05 2005-09-22 Pulmatrix, Inc. Formulations decreasing particle exhalation
US20070098644A1 (en) * 2005-10-31 2007-05-03 Richie's Pharmacy And Medical Supply, Incorporated Delivery of a combination therapy for asthma and chronic obstructive pulmonary disease
GB0604141D0 (en) * 2006-03-01 2006-04-12 Arrow Int Ltd Nebulizer formulation
KR20090129998A (ko) 2007-02-11 2009-12-17 맵 파마슈티컬스, 인코포레이티드 부작용 프로파일을 최소화하면서 편두통의 빠른 완화를 가능하게 하는 ｄｈｅ의 치료적 투여 방법
EP2124915A2 (en) 2007-02-19 2009-12-02 Cipla Limited Pharmaceutical combinations of at least two bronchodilators or of a bronchodilator with a corticosteroid
EP1982709A1 (en) * 2007-04-19 2008-10-22 CHIESI FARMACEUTICI S.p.A. Use of a composition comprising formoterol and beclomethasone dipropionate for the prevention or treatment of an acute condition of asthma
CN107412212B (zh) 2009-05-29 2021-01-22 珍珠治疗公司 经肺递送长效毒蕈碱拮抗剂及长效β2肾上腺素能受体激动剂的组合物及相关方法与系统
PL2538922T3 (pl) * 2010-02-25 2016-11-30 Formułowanie kompozycji do leczenia stanów zapalnych
WO2012007729A2 (en) * 2010-07-16 2012-01-19 Cipla Limited Pharmaceutical compositions
EP2448571B1 (en) 2010-08-30 2013-06-12 Pulmatrix, Inc. Respirably dry powder comprising calcium lactate, sodium chloride and leucine
EP2611438B1 (en) 2010-08-30 2020-04-01 Pulmatrix Operating Company, Inc. Dry powder formulations and methods for treating pulmonary diseases
CN102416179B (zh) 2010-09-28 2014-05-07 益得生物科技股份有限公司 用于哮喘的吸入性复方组合物
DK3470057T3 (da) 2010-09-29 2021-11-22 Pulmatrix Operating Co Inc Kationiske tørpulvere omfattende magnesiumsalt
MX354828B (es) 2010-09-29 2018-03-22 Pulmatrix Operating Co Inc Polvos secos de cationes metálicos monovalentes para inhalación.
JOP20120023B1 (ar) * 2011-02-04 2022-03-14 Novartis Ag صياغات مساحيق جافة من جسيمات تحتوي على واحد أو اثنين من المواد الفعالة لعلاج امراض ممرات الهواء الانسدادية او الالتهابية
CN107596518B (zh) 2012-02-29 2021-04-23 普马特里克斯营业公司 可吸入干粉剂
RU2504382C1 (ru) * 2012-06-13 2014-01-20 Шолекс Девелопмент Гмбх Ингаляционный препарат для лечения бронхиальной астмы и хронической обструктивной болезни легких и способ его получения
WO2014165303A1 (en) 2013-04-01 2014-10-09 Pulmatrix, Inc. Tiotropium dry powders
ITMI20130571A1 (it) 2013-04-10 2014-10-11 Zambon Spa Composizione farmaceutica contenente budesonide e formoterolo
GB201408387D0 (en) * 2014-05-12 2014-06-25 Teva Pharmaceuticals Europ B V Treatment of respiratory disorders
TW201735914A (zh) * 2015-12-22 2017-10-16 阿斯特捷利康公司 用於治療慢性阻塞性肺疾病之醫藥組成物
IT202000006442A1 (it) 2020-03-27 2021-09-27 Genetic S P A Budesonide 21-phosphate salts and pharmaceutical compositions containing the same

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4203401A (en) 1979-01-29 1980-05-20 General Motors Corporation Evaporative emissions canister
DK0416950T3 (da) 1989-09-08 1993-10-11 Glaxo Group Ltd Medikamenter
IL95590A (en) 1989-09-08 1996-06-18 Glaxo Group Ltd Medicinal preparations containing Salmetrol and Pluticasone Propionate
US5250286A (en) * 1990-05-07 1993-10-05 Aegis Technology, Inc. Treatment of chronic obstructive pulmonary disease (COPD) by inhalation of an imidazoline
PL164294B1 (pl) 1990-12-20 1994-07-29 Inst Farmaceutyczny Sposób otrzymywania diastereoizomeru /22R/-16a , 17a-butylidenodioksy-11 ß 21-dihydroksy-1,4-pregnadien-3,20-dionu PL
US5795564A (en) * 1991-04-05 1998-08-18 Sepracor, Inc. Methods and compositions for treating pulmonary disorders using optically pure (R,R)-formoterol
SE9302777D0 (sv) 1993-08-27 1993-08-27 Astra Ab Process for conditioning substances
US5119791A (en) 1991-06-07 1992-06-09 General Motors Corporation Vapor storage canister with liquid trap
US5444521A (en) 1991-07-15 1995-08-22 Canon Kabushiki Kaisha Image fixing device capable of controlling heating overshoot
AU673660C (en) * 1991-12-18 2002-07-25 Astrazeneca Ab New combination of formoterol and budesonide
EP1086697A2 (en) 1991-12-18 2001-03-28 AstraZeneca AB New combination of formoterol and budesonide
US5408977A (en) 1993-08-23 1995-04-25 Walbro Corporation Fuel tank with carbon canister and shut-off valve
BR9407686A (pt) 1993-10-01 1997-02-04 Astra Ab Processo e aparelho para o tratamento de um medicamento em pó finamente dividido uso do aparelho e aglomerados
SE9404080L (sv) * 1993-12-28 1995-06-29 Ciba Geigy Ag Förfarande för framställning av en optiskt ren enantiomer av formoterol
US5511957A (en) 1994-09-27 1996-04-30 Walbro Corporation High capacity fuel pump and filter combination
SE9700134D0 (sv) 1997-01-20 1997-01-20 Astra Ab New formulation
US5983956A (en) * 1994-10-03 1999-11-16 Astra Aktiebolag Formulation for inhalation
GB9519692D0 (en) * 1995-09-27 1995-11-29 Quillin Helen Atomising nozzle
US6277862B1 (en) 1995-11-24 2001-08-21 Smithkline Beecham S.P.A. Quinoline derivatives
US5651349A (en) 1995-12-11 1997-07-29 Chrysler Corporation Purge system flow monitor and method
SE9603669D0 (sv) 1996-10-08 1996-10-08 Astra Ab New combination
SE9700135D0 (sv) * 1997-01-20 1997-01-20 Astra Ab New formulation
SK184799A3 (en) 1997-06-27 2000-06-12 Astra Ab New combination of antiasthma medicaments
SE9703407D0 (sv) * 1997-09-19 1997-09-19 Astra Ab New use
US6598603B1 (en) * 1997-12-31 2003-07-29 Astra Aktiebolag Method for treating respiratory diseases
SE9802073D0 (sv) 1998-06-11 1998-06-11 Astra Ab New use
US5957114A (en) 1998-07-17 1999-09-28 Ford Motor Company Evaporative emission canister for an automotive vehicle
US5924410A (en) 1998-07-20 1999-07-20 Ford Motor Company Evaporative emission canister for an automotive vehicle
DZ2947A1 (fr) 1998-11-25 2004-03-15 Chiesi Farma Spa Inhalateur à compteur de dose sous pression.
US6004537A (en) 1998-12-18 1999-12-21 Baker Norton Pharmaceuticals, Inc. Pharmaceutical solution aerosol formulations containing fluoroalkanes, budesonide and formoterol
US6227862B1 (en) * 1999-02-12 2001-05-08 Advanced Drivers Education Products And Training, Inc. Driver training system
DE60016990T2 (de) 1999-02-26 2005-12-29 Walbro Corp., Cass City Fahrzeugbrennstoffsystem
SE9900834D0 (sv) 1999-03-09 1999-03-09 Astra Ab Novel combination
US6237574B1 (en) 1999-04-20 2001-05-29 Ford Motor Company Evaporative emission canister for an automotive vehicle
US6136075A (en) 1999-05-03 2000-10-24 Westvaco Corporation Automotive evaporative emissions canister adsorptive restraint system
JP3646217B2 (ja) 1999-07-08 2005-05-11 愛三工業株式会社 キャニスタモジュール
US6374811B1 (en) 2000-10-04 2002-04-23 Ford Global Technologies, Inc. System and method for minimizing fuel evaporative emissions from an internal combustion engine

Also Published As

Publication number Publication date
SA99200234B1 (ar) 2007-03-10
EP1085877A1 (en) 2001-03-28
NZ536279A (en) 2007-01-26
IL139921A0 (en) 2002-02-10
HUP0103108A3 (en) 2002-11-28
SE9802073D0 (sv) 1998-06-11
ID27937A (id) 2001-05-03
EE200000740A (et) 2002-04-15
NO20140823L (no) 2001-02-12
CN100389771C (zh) 2008-05-28
CZ300874B6 (cs) 2009-09-02
NO20130269L (no) 2001-02-12
NO20006253D0 (no) 2000-12-08
WO1999064014A1 (en) 1999-12-16
AU771715B2 (en) 2004-04-01
TR200003666T2 (tr) 2001-06-21
EP2266574A1 (en) 2010-12-29
IL139921A (en) 2006-10-05
DK1085877T3 (da) 2008-06-09
DE69938390T2 (de) 2009-03-05
RU2222332C2 (ru) 2004-01-27
CY1110376T1 (el) 2015-04-29
JP2002517450A (ja) 2002-06-18
TWI252756B (en) 2006-04-11
EP1085877B1 (en) 2008-03-19
KR20010052721A (ko) 2001-06-25
ZA200006943B (en) 2002-02-27
NO20006253L (no) 2001-02-12
ES2302384T3 (es) 2008-07-01
AR018410A1 (es) 2001-11-14
SK18882000A3 (sk) 2001-07-10
SK286252B6 (sk) 2008-06-06
AU4671099A (en) 1999-12-30
DE69938390D1 (de) 2008-04-30
MY129281A (en) 2007-03-30
US20040063676A1 (en) 2004-04-01
IS5752A (is) 2000-12-05
ATE389409T1 (de) 2008-04-15
CA2334411C (en) 2008-07-15
HK1035145A1 (en) 2001-11-16
EP1316311A1 (en) 2003-06-04
CN1305380A (zh) 2001-07-25
HUP0103108A2 (hu) 2002-05-29
PT1085877E (pt) 2008-05-13
US9295644B2 (en) 2016-03-29
US20010049396A1 (en) 2001-12-06
PL344665A1 (en) 2001-11-19
UA87956C2 (uk) 2009-09-10
CA2334411A1 (en) 1999-12-16
CZ20004593A3 (cs) 2001-04-11
EE05661B1 (et) 2013-06-17

Similar Documents

Publication Publication Date Title
BR9911073A (pt) Uso de uma composição compreendendo formoterol e budesonida para a prevenção ou tratamento de uma condição aguda de asma
BR9908030A (pt) Composição farmacêutica compreendendo uma ou mais unidades de dose oralmente ministráveis, e, processos para prepará-la, para uso da mesma, e para tratar uma condição ou distúrbio médico em um indivìduo em que tratamento com um inibidor da ciclooxigenase-2 é indicado
KR970704422A (ko) 투여용 약제학적 조성물
BRPI0317463B8 (pt) composto, composição farmacêutica compreendendo o mesmo e uso do referido composto no preparo de um medicamento para tratar uma doença amilóide de transtiretina
AR013506A1 (es) Uso de una composicion farmaceutica para la manufactura de un medicamento para ser usado en el tratamiento de enfermedades de obstruccion pulmonarcronica y de un kit que comprende formoterol o una sal o solvato del mismo y budesonida
BR0008699A (pt) Combinações de formoterol e furoato demometasona para asma
BR0116945A (pt) Uma preparação para prevenção de restenose
AR013614A1 (es) Nueva composicion que comprende una combinacion de esteroides, un kit que la contiene, el uso de la misma, el uso de dicho kit de formoterol y debudesonida en la fabricacion de un medicamento
BR9813811A (pt) &#34;composições farmacêuticas compreendendo micelas que compreendem glicocorticosteróide lipofìlico e apenas um único tensoativo&#34;
BR0208012A (pt) Usos de pelo menos duas drogas e um propelente hfa e de pelo menos uma composição farmaceêutica, e, inalador acondicionado para tratar asma
CA2136404A1 (fr) Composition solide mucoadhesive, therapeutique ou hygienique, pour administration par application sur la muqueuse buccale ou nasale
BR0114759A (pt) Utilização de inibidores da apoptose dos perìcitomas para o tratamento e/ou a prevenção da retinopatia diabética
KR970061244A (ko) 치매 치료용 약학 조성물
BR0309057A (pt) Formulações lìquidas com baixa dosagem em entecavir e uso
BR0210744A (pt) Combinação farmacêutica sinergìstica para a prevenção ou tratamento de diabetes
JP5161472B2 (ja) 鎮痛用組成物
CA2385755A1 (en) Prevention of colorectal cancer
BRPI0410374A (pt) composição farmacêutica que compreende valsartano
BR0212744A (pt) Formulações de cisplatina de toxicidade reduzida e métodos para uso das mesmas
US5849786A (en) Process for the treatment or prevention of herpes
WO2001068076A3 (en) D-enantiomer of dfmo and methods of use thereof for treating cancer
JP7164976B2 (ja) 外用医薬組成物
KR920703060A (ko) 제약학적 배합물
EP0272393A3 (en) Pharmaceutical combination
JP2003523920A5 (pt)

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: ALTERADA DE INT.CL: A61K 31/57, A61K 31/167, A61K 9/00, A61K 9/14, A61K 31/573, A61K 31/58, A61P 11/06

Ipc: A61K 31/57 (2007.10), A61K 31/167 (2007.10), A61K

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFERIMENTO DO PRESENTE PEDIDO, UMA VEZ QUE A MATERIA REIVINDICADA NO PRESENTE PEDIDO NAO APRESENTA NOVIDADE TENDO EM VISTA O DISPOSTO NOS ARTIGS 8O E 11 DA LEI 9279/96

B12B Appeal against refusal [chapter 12.2 patent gazette]